News

The patented carrier can be tailored to small molecules, peptides, protein and nucleic acids-based drugs. The PolyPid platform can be utilized to address numerous medical indications in various

The company has reported a net loss of $2.6m, or $0.05 loss per diluted share, compared to net income of $44.34m or $1.22 per diluted share, for the

Adenosine A2A, discovered by Heptares, is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. Heptares said it has stabilised the A2A

Originally developed by Hermes BioSciences, MM-398, was acquired by Merrimack in 2009. The tie up allows Merrimack to develop and commercialize MM-398 in all territories of the world

The multi-target drug discovery alliance was originally signed in 2004 for the co-identification and co-development of preclinical development candidates targeting various disease areas including CNS, inflammation, cardiometabolic and

NUVIGIL is indicated for the improvement of wakefulness in patients with excessive sleepiness associated with shift work disorder (SWD), treated obstructive sleep apnea (OSA), or narcolepsy. The six-week,

The orphan drug status provides the company for marketing MCD-386CR as a treatment for PSP for seven years. MCD-386 is a selective agonist (activator) for M1-type acetylcholine muscarinic

Revenue for the first quarter of 2011 was $14.7m, consisting of partial recognition of the non-refundable up-front and development milestone payments to date from the company’s corporate partners

Tullman was the co-founder, president and CEO of Ception Therapeutics, which was acquired by Cephalon, in April 2010, and currently serves as chairman of Vicept Therapeutics. Before Ception,